The data on cangrelor support approval of the fast-acting antiplatelet drug for reducing thrombotic cardiovascular events in patients with coronary artery disease who are undergoing percutaneous...
Serial blood pressure measurements during young adulthood appear to predict the risk of subclinical coronary artery calcification, a surrogate for CVD risk, in middle age, according to a report...
SNOWMASS, COLO. – A recent randomized trial provides physicians with important new guidance on how to manage antithrombotic therapy in patients requiring oral anticoagulation who develop an acute...
When the Food and Drug Administration in January granted marketing approval to a second transcatheter aortic valve replacement system for inoperable patients with aortic stenosis, the CoreValve...
Total United States health care costs could be lowered by billions of dollars per year if evidence-based guidelines for follow-up patient visits are established, according to the authors of a <link...
An incentivized, system-based approach to improve care for patients with diabetes and other chronic diseases appeared to pay off after just 3 years by significantly cutting the incidence of adverse...
Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been approved for the treatment of type 2 diabetes with a requirement that the manufacturer conduct postmarketing studies that address...
UPDATED Jan. 4, 2014
The federally funded program to produce a set of U.S. guidelines for hypertension management, a process more than 5 years in the making, came to an unusual end on...
DALLAS – A mere 28% of 1,013 surveyed New York–area women correctly identified cardiovascular disease as the No. 1 killer of women. And two-thirds of those women said their primary care provider is...